La Trobe
1164164_Veiga,C_2021.pdf (6.42 MB)

Myelodysplasia syndrome, clonal hematopoiesis and cardiovascular disease

Download (6.42 MB)
journal contribution
posted on 12.05.2021, 00:23 by CB Veiga, EM Lawrence, Andrew Murphy, MJ Herold, D Dragoljevic
The development of myelodysplasia syndromes (MDS) is multiphasic and can be driven by a plethora of genetic mutations and/or abnormalities. MDS is characterized by a hematopoietic differentiation block, evidenced by increased immature hematopoietic cells, termed blast cells and decreased ma-ture circulating leukocytes in at least one lineage (i.e., cytopenia). Clonal hematopoiesis of indeterminate potential (CHIP) is a recently described phenomenon preceding MDS development that is driven by somatic mutations in hemopoietic stem cells (HSCs). These mutant HSCs have a competitive advantage over healthy cells, resulting in an expansion of these clonal mutated leukocytes. In this review, we discuss the multiphasic development of MDS, the common mutations found in both MDS and CHIP, how a loss-of-function in these CHIP-related genes can alter HSC function and leukocyte development and the potential disease outcomes that can occur with dysfunctional HSCs. In particular, we discuss the novel con-nections between MDS development and cardiovascular disease.

History

Publication Date

02/04/2021

Journal

Cancers

Volume

13

Issue

8

Pagination

(p. 1968-1968)

Publisher

MDPI AG

Rights Statement

The Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.

Usage metrics

Journal Articles

Categories

Licence

Exports